Oma Fertility vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Oma Fertility operates affordable mini IVF clinics using a lower-stimulation protocol that reduces medication costs and side effects, making IVF accessible to more patients.
About
Oma Fertility is a fertility clinic company founded in 2019 that operates a network of fertility clinics using minimal stimulation IVF (mini IVF) as a primary treatment approach, offering IVF at significantly lower cost than conventional high-stimulation protocols. Mini IVF uses fewer and lower doses of fertility medications, reducing medication costs from $3,000-5,000 to a fraction of that amount while also decreasing the risk of ovarian hyperstimulation syndrome. Oma pairs this lower-cost clinical model with efficient clinic operations, transparent pricing, and subscription plans that make ongoing IVF cycles economically sustainable for patients who might otherwise not afford conventional IVF. The company has raised $40M and operates multiple clinic locations primarily in the Midwest and Southeast United States, targeting the large population of fertility patients who are priced out of conventional IVF at $20,000+ per cycle. Oma Fertility has positioned itself in the value segment of the fertility clinic market, complementing premium networks like Kindbody by serving cost-conscious patients who prioritize affordability and accessibility over premium clinic amenities.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.